Blocking survivin to kill cancer cells.
Altieri
Dario C
DC
Department of Cancer Biology, University of Massachusetts Medical School, Worcester, USA.
D000409:Alanine / Q000737:chemistry; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D016923:Cell Death; D045744:Cell Line, Tumor; D018076:DNA, Complementary / Q000378:metabolism; D005799:Genes, Dominant; D005821:Genetic Techniques; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D005810:Multigene Family; D009154:Mutation; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000737:chemistry; D010957:Plasmids / Q000378:metabolism; D017354:Point Mutation; D011379:Prognosis; D000077022:Survivin; D013912:Threonine / Q000737:chemistry
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D018076:DNA, Complementary; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D000077022:Survivin; D013912:Threonine; D000409:Alanine